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Summary
 
The recruitment of eosinophils into the airways after allergen exposure is dependent on inter-
leukin (IL) 5 secreted from antigen-specific CD4
 
1
 
 T cells of the T helper cell (Th) 2 subset.
However, while it is established that costimulation through CD28 is required for TCR-medi-
ated activation and IL-2 production, the importance of this mechanism for the induction of a
Th2 immune response is less clear. In the present study, we administered the fusion protein
CTLA-4 immunoglobulin (Ig) into the lungs before allergen provocation to determine
whether CD28/CTLA-4 ligands are required for allergen-induced eosinophil accumulation
and the production of Th2 cytokines. Administration of CTLA-4 Ig inhibited the recruitment
of eosinophils into the lungs by 75% and suppressed IgE in the bronchoalveolar lavage fluid.
CTLA-4 Ig also inhibited the production of IL-4, IL-5, and IL-10 by 70–80% and enhanced
interferon-
 
g
 
 production from CD3–T cell receptor–activated lung Thy1.2
 
1
 
 cells. Allergen
exposure upregulated expression of B7-2, but not B7-1, on B cells from the lung within 24 h.
Moreover, airway administration of an anti-B7-2 monoclonal antibody (mAb) inhibited eosin-
ophil infiltration, IgE production, and Th2 cytokine secretion comparable in magnitude to that
observed with CTLA-4 Ig. Treatment with an anti-B7-1 mAb had a small, but significant ef-
fect on eosinophil accumulation, although was less effective in inhibiting Th2 cytokine pro-
duction. The anti-B7-2, but not anti-B7-1, mAb also inhibited antigen-induced airway hyper-
responsiveness in vivo. In all of the parameters assessed, the combination of both the anti-B7-1
and anti-B7-2 mAb was no more effective than anti-B7-2 mAb treatment alone. We propose
that strategies aimed at inhibition of CD28 interactions with B7-2 molecules may represent a
novel therapeutic target for the treatment of lung mucosal allergic inflammation.
 
B
 
ronchial asthma is characterized by the infiltration of
eosinophils into the airway submucosa (1). Activation
of eosinophils with the subsequent secretion of highly
charged granular cationic proteins such as major basic pro-
tein is believed to be important in the pathogenesis of
bronchial asthma (2–4). While the precise mechanisms by
which eosinophils are recruited into the lungs are not fully
understood, there is increasing evidence suggesting that ac-
tivation of antigen-specific CD4
 
1
 
 T cells of the Th2 subset
in the lungs resulting in IL-5 secretion plays a major role in
allergic inflammation of the airways (5–7).
T cell activation requires interaction between the TCR
and specific antigen, presented in the form of processed
peptides in association with MHC class II molecules. How-
ever, for complete T cell activation, a second signal termed
costimulation is required (8, 9). The most widely studied
costimulatory molecule is CD28, which is constitutively
expressed on the surface of both CD4
 
1
 
 and CD8
 
1
 
 T cells.
Activation of CD28 in conjunction with the CD3–TCR
complex is required for T cell proliferation and IL-2 pro-
duction (10–12). In the absence of CD28-mediated signal-
ing, a state of unresponsiveness or anergy develops (9–11).
The natural ligands for CD28 have more recently been
identified as B7-1 or CD80 (13–15), and B7-2 or CD86
(16, 17), and have been demonstrated to be present on the
surface of antigen-pulsed B cells (13–15) and dendritic cells
(18) and may account for the efficacy of these cells as
APCs.
B7-1 and B7-2 also bind to CTLA-4, a homologue of
CD28 (16, 19). A soluble chimeric fusion protein consist-
ing of the extracellular domain of CTLA-4 and a human 
 
g
 
-1
constant region, CTLA-4 Ig (20), binds to both B7-1 and
B7-2 with an affinity 20 times greater than CD28, and in-
hibits CD28– and CTLA-4–mediated signaling (19–22). In
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vitro studies using murine and human cells have demon-
strated that CTLA-4 Ig inhibits T cell proliferation and IL-2
production, and induces a state of T cell unresponsiveness
(19–22). However, while it is clearly established that CD28-
mediated signaling is required for IL-2 production, the
requirement of costimulation through CD28 for the in-
duction of a Th2 immune response is less clear. In the
present series of experiments, we have administered CTLA-4
Ig into the airways before aerosol antigen challenge to de-
termine whether costimulation through these molecules is
required for the recruitment of eosinophils into the lungs
and the production of Th2 cytokines. To further delineate
the involvement of B7-1 and/or B7-2, the expression of
these molecules on lung B cells after allergen provocation
was assessed and neutralizing mAbs to either B7-1 and/or
B7-2 were administered into the lung before allergen prov-
ocation. The results of this study indicate that allergen ex-
posure selectively upregulates B7-2 expression and that
costimulation through this molecule is required for the in-
duction of a lung mucosal Th2 immune response and for
allergen-induced altered airway responsiveness.
 
Materials and Methods
 
Antibodies and Cytokines
 
The CTLA-4 Ig used is a fusion protein between the extracel-
lular domain of murine CTLA-4 and human 
 
g
 
-1 obtained from a
CTLA-4 Ig–producing hybridoma (20) provided by Dr. Peter
Lane (Basel Institute of Immunology, Basel, Switzerland). Super-
natants were then concentrated and purified over a protein A col-
umn. PE-labeled Thy1.2 (30-H12), PE-labeled B220 (RA3-
6B2), FITC-labeled B7-1 (16-10A1), FITC-labeled and purified
B7-2 (GL-2), and CD16/CD32 (2.4G2, Fc Block
 
Ô
 
) were pur-
chased from PharMingen, (San Diego, CA). Purified B7-1 (16-
10A1; reference 23) was obtained from Dr. Hans Reiser (Dana
Farber Cancer Institute, Boston, MA). Human recombinant IL-2
and anti-CD3 (2C11) was obtained from Ciba-Geigy AG. (Basel,
Switzerland).
 
In Vivo Experiments
 
Quantification of Eosinophil Recruitment to the Lung. 
 
Sv129 mice (20–
25 g) of either sex were immunized intraperitoneally with 10 
 
m
 
g
of OVA (grade V; Sigma Chemical Co., St. Louis, MO) in 0.2 ml
of alum (Serva, Heidelberg, Germany). 10 d later, animals were
anesthetized by inhaled 2% Forene
 
Ô
 
 (isofluran; Abbott, Cham,
Switzerland) and 100 
 
m
 
g of CTLA-4 Ig administered to the lungs
(in a volume of 50 
 
m
 
l) by the intranasal route. Control mice were
treated with 100 
 
m
 
g of human 
 
g
 
-1 as the appropriate control an-
tibody. In preliminary experiments, we have used Evans blue dye
to document that intranasal delivery results in 75% of the dye de-
posited in the airways, with no detectable dye in the esophagus or
stomach. Moreover, studies using an anti-Fas mAb, which when
given systemically were fatal due to fulminant hepatitis, did not
induce mortality when given intranasally, supporting the argu-
ment that administration of agents via this route does not reach
the systemic circulation (24).
In a separate series of experiments, we administered 100 
 
m
 
g of
mAbs to B7-1 (16-10A1) and/or B7-2 (GL-2) (also in a volume
of 50 
 
m
 
l) via the intranasal route. Control mice received 100 
 
m
 
g
of rat IgG as an isotype control antibody. 4 h after each antibody
treatment, mice were placed in a plastic box and exposed, while
conscious, to an aerosol of OVA (50 mg/ml), of which 90% of
the particles are 
 
,
 
5 
 
m
 
m in size, for 20 min daily for a total of 5 d.
Control mice were exposed to an aerosol of PBS for the same
time period. 72 h after the last antigen inhalation, mice were
anesthetized with urethane, the trachea cannulated, and broncho-
alveolar lavage (BAL)
 
1
 
 performed by four repeated lavages with
0.3 ml of PBS injected into the lungs via the trachea. Total cell
counts were performed, cytospins prepared (Shandon, Scientific
Ltd., Cheshire, U.K.), stained with Diff-Quik
 
Ò
 
 (Baxter Dade
AG., Dudingen, Switzerland), and a differential count of 200 cells
was performed.
 
In Vitro Experiments
 
Determination of BAL Fluid IgE. 
 
Total IgE in the BAL fluid
was determined by ELISA as described previously (25) with the
following alterations. In brief, microtiter plates were coated with
rat anti–murine IgE 3B-39 (04-6100; Zymed Labs., Inc., S. San
Francisco, CA). After incubation with dilutions of BAL fluid,
sample-bound mouse IgE was detected with biotinylated rat anti–
murine IgE 3-11. Data were expressed as total IgE per ml of BAL
fluid. The limit of detection of the assay was 2 ng/ml of IgE.
 
Purification of Lung T Cells. 
 
To analyze the lung T cell cyto-
kine profile, experiments were performed 72 h after the last anti-
gen challenge. After the four repeated lavages for assessment of
the inflammatory cell infiltrate, the lungs were perfused via the
right ventricle with 5 ml of PBS containing 100 U/ml of heparin
to remove any blood and intravascular leukocytes. The lungs were
then removed and placed into DMEM containing 10% FCS,
2-mercaptoethanol (50 
 
m
 
M), sodium pyruvate (1 mM), Hepes
(10 mM), and gentamycin (50 
 
m
 
g/ml). The lungs were then gently
homogenized, the cell suspension was filtered through a 70-
 
m
 
M fil-
ter, and lymphocytes enriched over a single step Ficoll gradient. B
cells were depleted from the cell suspension using magnetic sheep
anti–mouse Ig beads (Dynabeads, Nycomed, Norway). Cells were
then labeled with Thy1.2-PE and purified by flow cytometry
(Beckton Dickinson, San Jose, CA) as described previously (5). In
all experiments, purity was 
 
.
 
99% Thy1.2
 
1
 
.
 
Cell Culture. 
 
Lung Thy1.2
 
1
 
 cells were then plated at a con-
centration of 2 
 
3
 
 10
 
5
 
 in 96-well microtiter plates coated with an
anti-CD3 antibody (2C11, 50 
 
m
 
g/ml). Cells were cultured for 72 h
in the presence of human IL-2 (200 U/ml). Supernatants were
harvested and cytokine production determined by ELISA as de-
scribed elsewhere (5). The limits of detection were IL-4, 0.5 U/ml;
IL-5, 100 U/ml; IL-10, 10 U/ml, IL-2, 0.2 U/ml; IFN-
 
g
 
, 50 U/ml.
 
Immunofluoresence and Flow Cytometry Analysis.
 
To determine
the expression of CD28 ligands on lung B lymphocytes 24 h after the
first, third, or fifth aeroallergen challenge, lymphocytes were en-
riched from the lung as described above and stained with anti-
B220-PE. Nonspecific binding to Fc
 
g
 
 receptors was then blocked
by incubating cells at 4
 
8
 
C for 30 min with CD16/CD32 mAb
(2.4G2). Cells were then washed twice and incubated for a fur-
ther 30 min with FITC anti-B7-1 or FITC-B7-2. Expression of B7
molecules after allergen exposure was compared to either before
challenge or after repeated challenge with PBS. Fluorescence was
analyzed by flow cytometry, gated on the region of B220
 
1
 
 cells
(FACScan
 
Ò
 
) using consort 30 software, and 10,000 events acquired.
 
1
 
Abbreviations used in this paper:
 
 AHR, airway hyperresponsiveness; BAL,
bronchoalveolar lavage; MCh, methacholine. 
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Measurement of Airway Hyperresponsiveness In Vivo. 
 
Airway re-
sponsiveness was measured 24 h after the last aerosol challenge by
recording respiratory pressure curves by whole body plethysmog-
raphy (Buxco
 
Ò
 
, EMKA Technologies, Paris, France) in response
to inhaled methacholine (Aldrich-Chemie, Steinhein, Germany)
at a concentration of 3 
 
3
 
 10
 
2
 
2
 
 M for 20 s, as described previously
(26, 27). This method allows measurements of spontaneous
breathing in a nonrestrained mouse. Airway responsiveness was
expressed in enhanced pause (Penh), a calculated value, which
correlates with measurement of airway resistance, impedance, and
intrapleural pressure in the same mouse. Penh 
 
5
 
 (Te/Tr 
 
2
 
 1) 
 
3
 
(Pef/Pif) (Te, expiration time; Tr, relaxation time; Pef, peak ex-
piratory flow; Pif, peak inspiratory flow 
 
3
 
 0.67 
 
5
 
 coefficient;
reference 28). The relaxation time is the time it takes for the box
pressure to change from a maximum to a user-defined percentage
of the maximum. In this study, Tr measurement begins at the
maximum box pressure and ends at 40%. Immunized mice were
treated with either control Ig, anti-B7-1, and/or anti-B7-2 mAb
and exposed to either PBS or OVA.
 
Results
 
CTLA-4 Ig Inhibits Antigen-induced Eosinophil Recruitment
to the Lungs. 
 
Exposure to five repeated aerosol provoca-
tions of OVA induced a selective infiltration of eosinophils
into the airways as assessed by BAL (40.0 
 
6
 
 11.0 eosino-
phils/ml 
 
3
 
 10
 
5
 
, 
 
n
 
 
 
5
 
 6). Administration of the human 
 
g
 
-1
as the isotype-matched control antibody 4 h before the first
allergen provocation had no significant effect on antigen-
induced eosinophil recruitment (38.9 
 
6
 
 6 eosinophils/ml 
 
3
 
10
 
5
 
, 
 
P
 
 
 
.
 
0.1, 
 
n
 
 
 
5
 
 6). Pretreatment with 100 
 
m
 
g of CTLA-
4 Ig induced a marked attenuation in the recruitment of
eosinophils into the airways (7.9 
 
6
 
 2.4 eosinophils/ml 
 
3
 
10
 
5
 
, 
 
n
 
 
 
5
 
 6, 
 
P
 
 
 
,
 
0.05, Fig. 1). Administration of CTLA-4 Ig
before PBS provocation of immunized animals failed to in-
duce any inflammatory changes in the airways (Fig. 1).
 
CTLA-4 Ig Inhibits the Local IgE Production in the Lungs.
 
Repeated allergen provocation increased levels of IgE in
the BAL fluid as compared to PBS-exposed animals (PBS
challenged, 
 
,
 
2 ng/ml, 
 
n
 
 
 
5
 
 3; antigen challenged, 72 
 
6
 
 14
ng/ml, 
 
n
 
 
 
5
 
 8, 
 
P
 
 
 
,
 
0.01). Local airway administration of
CTLA-4 Ig inhibited the production of IgE in the BAL
fluid (9.7 
 
6
 
 2.9 ng/ml, 
 
n
 
 
 
5
 
 5, 
 
P
 
 
 
,
 
0.001; Fig. 2). In con-
trast, CTLA-4 Ig failed to suppress total serum IgE (data
not shown).
 
CTLA-4 Ig Inhibits Th2 Cytokine Production and Enhances
IFN-
 
g
 
 Production. 
 
Activation of FACS
 
Ò
 
 purified Thy1.2
 
1
 
cells from the lung via the CD3–TCR complex from im-
munized, PBS-challenged mice produced IL-2 and IFN-
 
g
 
,
with no detectable IL-4, IL-5, or IL-10. In contrast, re-
peated allergen provocation of immunized mice treated with
Figure 1. Inhibition of eosinophil infiltration by CTLA-4 Ig. Immu-
nized mice were treated with either CTLA-4 Ig (striped bar) or human g-1
as the isotype control Ig (filled bar) before allergen challenge. Immunized,
PBS-challenged mice were also treated with CTLA-4 Ig and are shown
for comparison (open bar). Data are expressed as mean 6 SEM of eosino-
phils/ml 3 105 for n 5 4–7 mice. Statistical significance (*) was deter-
mined by a Student’s t test and a value of P ,0.05 was considered to be
significant.
Figure 2. Inhibition of IgE in the BAL fluid by CTLA-4 Ig. Immu-
nized mice were treated with either CTLA-4 Ig (striped bar) or human g-1
as the isotype control Ig (filled bar) before allergen challenge. Immunized,
PBS-challenged mice were also treated with CTLA-4 Ig and are shown
for comparison. Data are expressed as mean 6 SEM of IgE in ng/ml for
n 5 4–7 mice. Statistical significance (*) was determined by a Student’s t
test and a value of P ,0.05 was considered to be significant.
Figure 3. Effect of CTLA-4 Ig on cytokine production from in vitro–activated lung T cells. Immunized mice were treated with either CTLA-4 Ig
(striped bars) or human g-1 (filled bars) before allergen challenge. Immunized, PBS-challenged mice were also treated with CTLA-4 Ig and are shown for
comparison (open bars). Data are expressed as mean 6 SEM of triplicate cultures and shown in U/ml.1674 B7-2 and Th2 Lung Response
human g-1 resulted in the secretion of high amounts of
IL-4, IL-5, and IL-10, elevated levels of IL-2, and reduced
amounts of IFN-g (Fig. 3). Pretreatment with CTLA-4 Ig
inhibited the production of Th2 cytokines by 70–80%, en-
hanced the production of IFN-g by threefold, but had no
significant effect on IL-2 production compared to control
Ig-treated mice.
B7-2, but Not B7-1, Is Upregulated on Lung B Cells after
Allergen Provocation.  We next investigated whether anti-
gen provocation leads to the expression of the CD28 coun-
terligands B7-1 and B7-2. B cells obtained from the lungs
of immunized mice before challenge expressed low levels
of B7-1 and B7-2 (Fig. 4, a and b). However, B7-2 expres-
sion was markedly upregulated within 24 h after the first al-
lergen exposure and was maintained after three or five al-
lergen provocations (data not shown). In contrast, B7-1
was not upregulated on lung B cells at any time point after
antigen challenge (Fig. 4, c and d).
B7-2 Is the Primary CD28 Counterligand Required for the
Induction of a Th2 Immune Response.  It then became im-
portant to determine whether B7-1, B7-2, or both mole-
cules are required for the induction of a lung Th2 immune
response. Anti-B7-2 mAb treatment inhibited the recruit-
ment of eosinophils in the lung by .85%, compared to
control Ig-treated mice (control Ig, 24.6 6 3.6 eosino-
phils/ml  3 105, n 5 10; anti-B7-2 mAb, 3.07 6 1.1 eosin-
ophils/ml 3 105, n 5 5, P ,0.005; Fig. 5). In contrast, the
anti-B7-1 mAb had a minor, although significant, inhibi-
tory effect on eosinophil recruitment into the lung (anti-B7-1
mAb, 16.8 6 3.8 eosinophils/ml 3 105, n 5 9, P ,0.05).
However, the combination of both mAbs was no more ef-
fective than anti-B7-2 mAb alone (2.4 6 0.80 eosinophils/
ml 3 105, n 5 10, P .0.05, compared to anti-B7-2 mAb
alone). In addition, in vivo treatment with anti-B7-2 mAb
inhibited the production of IL-4 and IL-5 and enhanced
production of IFN-g from purified lung T cells activated
through the CD3–TCR complex, whereas treatment with
anti-B7-1 mAb had a minor effect on Th2 cytokine secre-
tion (Fig. 6). The combination of both mAbs was no more
effective than anti-B7-2 mAb in inhibiting Th2 cytokine
production. Finally, measurement of IgE levels in the BAL
supported the principle role for costimulation through B7-2,
as IgE production was suppressed by the anti-B7-2 mAb
(control Ig, 65 6 9 ng/ml; anti-B7-2 mAb, 12 6 5 ng/ml,
P ,0.05), but not by the anti-B7-1 mAb (57 6 12 ng/ml,
P .0.05). The combination of both mAbs was no more ef-
Figure 4. Representative FACSÒ analysis of expression of B7-1 and
B7-2 on lung B2201 cells before (a and b) and 24 h after antigen chal-
lenge in immunized mice. Cells were stained with PE-B220 alone (solid
lines) or PE-B220 and FITC-B7-1 or B7-2 (dotted lines). Data are ex-
pressed as histograms of B7 expression after gating on B220 positive cells.
Data are representative of three separate experiments.
Figure 5. Effect of mAbs to B7-1 (open bar), B7-2 (striped bar), or B7-1
and B7-2 (shaded bar) on antigen-induced eosinophil infiltration. Control
mice were treated with rat IgG (filled bar). Data are expressed as mean 6
SEM of eosinophils/ml 3 105 for n 5 9–10 mice. Statistical significance
(*) was determined by a Student’s t test and a value of P ,0.05 was con-
sidered to be significant.
Figure 6. Inhibition of IgE in the BAL fluid by anti-B7-2 mAb. Im-
munized mice were treated with either anti-B7-1 (open bar), anti-B7-2
mAb (striped bar), anti-B7-1 and anti-B7-2 (shaded bar), or rat IgG (filled
bar) as the isotype control Ig before allergen challenge. Data are expressed
as mean 6 SEM of IgE in ng/ml for n 5 6–8 mice. Statistical significance
(*) was determined by a Student’s t test and a value of P ,0.05 was con-
sidered to be significant.1675 Tsuyuki et al.
fective than anti-B7-2 mAb in IgE production (14 6 8 ng/
ml; Fig. 7).
B7-2, but Not B7-1, Is Required for the Induction of Airway
Hyperresponsiveness In Vivo. We next investigated whether
B7-1 and/or B7-2 contribute to the development of air-
way hyperresponsiveness (AHR) to methacholine (MCh).
Allergen provocation of immunized mice treated with con-
trol rat Ig resulted in the development of AHS (baseline
Penh, 0.37 6 0.04; after MCh, 2.8 6 0.27, n 5 5), as com-
pared to immunized mice treated with control rat Ig and
exposed to PBS (baseline Penh, 0.39 6 0.01; after MCh
0.56 6 0.03, n 5 4, P .0.05; Fig. 8 A). There was no
change in AHR in PBS-exposed mice that were treated
with either B7-1 and/or B7-2 mAb (data not shown). Pre-
treatment with anti-B7-2 mAb abrogated the development
of allergen-induced AHR (baseline Penh, 0.39 6 0.04; af-
ter MCh, 0.90 6 0.33, P ,0.05). In contrast, anti-B7-1
mAb had no significant effect, and the MCh response was
comparable to that observed in Ig-treated, antigen-exposed
mice. (baseline Penh, 0.35 6 0.03; after MCh, 3.38 6
0.85, P 5 0.48). Pretreatment with the combination of
anti-B7-1 and B7-2 mAbs was no more effective than anti-
B7-2 mAb treatment alone AHR (baseline Penh, 0.36 6
0.02; after MCh, 0.70 6 0.16, P .0.05), compared to
anti-B7-2 mAb treatment alone (Fig. 8 B).
Discussion
Activation of antigen-naive CD41 T cells produce pre-
dominately IL-2. However, under the influence of IL-4,
these cells differentiate into a phenotype that produces high
levels of Th2 cytokines (29–31). In recent years, evidence
has increased to suggest that activation of antigen-specific
CD41 Th2 cells in the lungs of allergic individuals plays a
central role in the pathogenesis of bronchial asthma by pro-
viding IL-4, which is essential for B cell switching to IgE to
occur (32), and IL-5, which is required for eosinophil mo-
bilization and/or accumulation (5–7). It is now clearly es-
tablished that in addition to interactions between peptides
bound to MHC class II molecules and the CD3–TCR-a/b
complex, a second signal is required. CD28-mediated sig-
naling via its natural ligands, B7-1 and B7-2, provides the
signal necessary for T cell proliferation and IL-2 gene tran-
scription (11–18). However, the costimulatory signals that
are required for the induction of a Th2 immune response
are less clear. In the present study, we use the fusion pro-
Figure 7. Inhibition of Th2
cytokine production by anti-B7-
2 mAb from in vitro–activated
lung T cells. Immunized mice
were treated with anti-B7-1
and/or anti-B7-2 mAb or rat
IgG as the isotype control Ig be-
fore allergen challenge. Data are
expressed as mean 6 SEM of
triplicate cultures and shown in
U/ml.
Figure 8. Inhibition of air-
way hyperresponsiveness to
methacholine by an anti-B7-2
mAb. (A) Mice were immunized
and exposed to either an aerosol
of PBS or OVA for 5 consecu-
tive days. (B) Effect of anti-B7-1
and/or B7-1 mAb on antigen-
induced AHR. Control mice
were treated with rat IgG. Re-
sults are expressed as the mean 6
SEM of the Penh before (open
bar) and after (filled bar). MCh
provocation for n 5 4–6 animals.
Statistical significance (*) was de-
termined by a Student’s t test and
a value of P ,0.05 was consid-
ered to be significant.1676 B7-2 and Th2 Lung Response
tein CTLA-4 Ig to demonstrate that costimulation through
CD28 ligands is required for the local production of IgE
and the recruitment of eosinophil into the lungs. These ob-
servations are supported by the demonstration that CTLA-4
Ig treatment suppresses the production of IL-4, IL-5, and
IL-10 from lung T cells. In contrast, pretreatment with
CTLA-4 Ig enhanced the production of IFN-g from lung
T cells by threefold. Thus, in the absence of costimulation
through CD28 ligands, cells can default to a phenotype that
produces less Th2 cytokines and more IFN-g. As IFN-g
has been shown to inhibit the proliferation of Th2 cells
(33), reciprocally regulate IL-4-dependent IgE production
(34), and can inhibit the accumulation of eosinophils into
the lung in vivo (35), it remains to be clarified, using anti-
bodies to IFN-g or mice with a disrupted IFN-g system,
whether CTLA-4 Ig suppresses eosinophil infiltration and
IgE production at least in part by the upregulation of IFN-g
production.
The requirement of CD28 as a costimulatory molecule
for activation of Th2 cells is controversial at present. In vitro
studies have demonstrated that Th2 cells can use other co-
stimulatory signals besides CD28, and attention has focused
on an important role for IL-1 (36). More recently, IL-4
production has been shown to be independent of CD28-
mediated stimulation, although CD28 signaling was required
for inducing responsiveness to IL-4 (37). CTLA-4 Ig has
also been demonstrated to inhibit alloantigen-specific re-
sponses, and IL-2 and IFN-g, but not IL-4 secretion (38).
In addition, antigen-specific stimulation of CD41 T cells
from TCR transgenic mice have shown that IL-4 secretion
from Th2 cells is relatively independent of costimulation
through CD28 (38). These in vitro observations are also
supported by in vivo experiments showing that CTLA-4 Ig
specifically inhibits the production of Th1 cytokines, but
spares the production of Th2 cytokines in a rat renal allo-
graft model (39). In contrast, after infection with Heligmo-
somoides polygyrus, CD28-mediated stimulation is required
for IL-4 production and B cell switch to IgE production,
although the development of a peripheral blood eosino-
philia was largely independent of CD28-mediated costimu-
lation (40). Likewise, after infection with Leishmania major
(41) or in a primary immune response induced by anti-IgD
(42), CTLA-4 Ig inhibits the appearance of IL-4–produc-
ing cells. However, in these two models, the production of
IL-5 and IL-10 was independent of costimulation through
CD28. Interestingly, administration of CTLA-4 Ig treat-
ment several days after treatment with either anti-IgD or
H. polygyrus failed to inhibit the development of IgE-pro-
ducing cells (40, 42). These results suggest that in vivo
priming of naive T cells generally requires B7-CD28–medi-
ated costimulation, whereas activation of differentiated Th2
cells is largely B7 independent.
If CD28 is required for differentiation towards a Th2
immune response, it still remains unclear whether activa-
tion of CD28 is mediated by either B7-1 and/or B7-2. B7
molecules have been shown to be expressed on activated B
cells (14–17), functional mature dendritic cells (18), and
more recently, on activated CD41 and CD81 T cells (43).
However, the expression of these molecules is differentially
controlled in that B7-2 expression is upregulated within 6 h
of B cell activation after LPS, Con A, or antigen-specific
stimulation, whereas B7-1 was not increased until 72 h
later. Moreover, while LPS and Con A induced B7-1 ex-
pression, cross-linking of the Ig receptor failed to upregu-
late B7-1 expression (44, 45). These in vitro studies are
supported by the present in vivo observations that 24 h af-
ter aeroantigen exposure, B7-2, but not B7-1, expression was
increased on lung B cells and expression was maintained af-
ter the repeated antigen provocations (data not shown). How-
ever, it is important to note that despite the lower level of
expression of B7-1, the slower off-rate of B7-1, compared
to B7-2, may allow this molecule to exert potent costimu-
latory functions (46). In addition, the ability of B7-1 and
B7-2 to bind to distinct CD28 determinants with different
affinities (47) raises the possibility that these molecules play
distinct functions (48). Freeman et al. have suggested that
repeated alloantigen stimulation by B7-2–, but not B7-1–trans-
fected cells selectively primes naive cells for IL-4 produc-
tion (49). Likewise, in a recent study using 1-Ad–restricted,
antigen-specific CD41 T cells obtained from transgenic
mice, it was shown that anti-B7-2 mAb markedly sup-
pressed the development of IL-4– and IL-10–producing
cells, whereas blockade of B7-1 facilitated differentiation to-
wards IL-4 production and inhibited IFN-g secretion (50).
To investigate the role of these two molecules in the in-
duction of the allergic inflammatory response, we adminis-
tered neutralizing mAbs to B7-1 and/or B7-2 directly into
the lungs. Our observations suggest that costimulation through
B7-2 is the primary CD28 counterreceptor involved in the
induction of a lung mucosal Th2 immune response, since
administration of the anti-B7-2 mAb inhibited the recruit-
ment of eosinophils into the lungs and Th2 cytokine pro-
duction. However, we can not rule out a small contribution
of B7-1–mediated costimulation, since eosinophil accumu-
lation was reduced by 25%. However, coadministration of
both mAbs was no more effective than treatment with anti-
B7-2 alone, supporting the evidence that B7-2 is the prin-
cipal CD28 ligand required in this response. Distinct roles
for B7 ligands have also been suggested in another in vivo
study where neutralization of B7-2 inhibited the produc-
tion of Th2 cytokines, enhanced the production of IFN-g,
and was associated with enhanced disease severity in a
model of experimental allergic encephalomylitis (51). Like-
wise, differential functions for B7-1 and B7-2 have also
been suggested in the development of diabetes in nonobese
diabetic mice whereby anti-B7-2 mAb inhibited the devel-
opment of diabetes, compared to anti-B7-1 mAb, which
accelerated the disease development (52). It therefore be-
came important to determine whether B7-2–mediated co-
stimulation was not only associated with the inflammatory
response in the lungs, but was also implicated in a patho-
physiological-relevant response. Our results show that the
induction of airway hyperresponsiveness, which is a char-
acteristic feature of bronchial asthma, was abrogated by
treatment with the anti-B7-2 mAb. In contrast, administra-
tion of the anti-B7-1 mAb provided no protection, despite1677 Tsuyuki et al.
the small reduction in the number of eosinophils in the
lungs after allergen provocation. Taken together, we sug-
gest that interaction of B7-2 with CD28 is important in the
development of a lung inflammatory response and is essen-
tial for the induction of airway hyperresponsiveness. Nev-
ertheless, further studies are required to elucidate whether
B7-1 and B7-2 also provide distinct costimulatory functions
during different immune responses (soluble protein antigens
compared to intact pathogens), or whether both molecules
can elicit similar responses with the appropriate cytokine
secretion.
In conclusion, repeated allergen provocation results in
the commitment of cells to the Th2 phenotype, the selec-
tive recruitment of eosinophils to the lung, and the pro-
duction of IgE, which is dependent on the activation of
CD28 ligands. In particular, we suggest an important role
primarily for B7-2, based on the selective upregulation of
this molecule, the marked suppression of lung Th2 mucosal
immune responses, and abrogation of airway hyperrespon-
siveness after allergen exposure by the anti-B7-2 mAb. These
observations open up the attractive therapeutic potential
that inhibiting B7-2–CD28 interactions in the lungs of al-
lergic individuals may lead to the development of novel
therapies for the treatment of allergic lung disease.
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